Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALO-02 weight-matched placebo
Drug: crushed oxycodone IR 30 mg
Drug: oxycodone weight-matched placebo
Drug: crushed ALO-02 30 mg/3.6 mg

First Posted Date: 2013-01-24

Last Posted Date: 2017-07-17

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT01775189

Locations: 🇨🇦
INC Research Toronto Inc., Toronto, Ontario, Canada

Safety And Tolerability Study Of BID Titration Scheme With PF-05089771

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-05089771

First Posted Date: 2013-01-21

Last Posted Date: 2013-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT01772264

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Ibuprofen 5% Topical Gel CIPT

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Topical gel vehicle
Drug: Ibuprofen 5% topical gel
Drug: Sodium lauryl sulfate 0.2%
Drug: Sodium chloride solution 0.9% (saline)

First Posted Date: 2013-01-18

Last Posted Date: 2013-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT01771822

Locations: 🇺🇸
Pfizer Investigational Site, Carlstadt, New Jersey, United States

Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia

Phase 2

Completed

Conditions: Inherited Erythromelalgia

Interventions: Drug: Placebo
Drug: PF-05089771

First Posted Date: 2013-01-16

Last Posted Date: 2019-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT01769274

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Phase 2

Completed

Conditions: Meningitis, Meningococcal, Serogroup B

Interventions: Biological: rLP2086

First Posted Date: 2013-01-15

Last Posted Date: 2018-12-20

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT01768117

Locations: 🇺🇸
Frontage Clinical Services (Formally ABR), Hackensack, New Jersey, United States

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3

Completed

Conditions: Metastatic or Unresectable Cutaneous Melanoma

Interventions: Drug: MEK162
Drug: Dacarbazine

First Posted Date: 2013-01-08

Last Posted Date: 2021-03-22

Lead Sponsor: Pfizer

Target Recruit Count: 402

Registration Number: NCT01763164

Locations: 🇺🇸
Harry and Jeannette Weinberg Cancer Institute @Franklin Square, Baltimore, Maryland, United States
🇺🇸
The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
🇺🇸
St. Luke's Hospital - Allentown Campus, Allentown, Pennsylvania, United States

and more 188 locations

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders

Interventions: Drug: Pf-05175157
Drug: placebo
Drug: midazolam

First Posted Date: 2012-12-31

Last Posted Date: 2012-12-31

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01757756

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement

Phase 4

Completed

Conditions: Fecal Analysis

Interventions: Dietary Supplement: ProNutrients Probiotic

First Posted Date: 2012-12-28

Last Posted Date: 2013-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT01757054

Locations: 🇺🇸
Pfizer Investigational Site, Boston, Massachusetts, United States

A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Radiation: [14C]-PD-0332991

First Posted Date: 2012-12-27

Last Posted Date: 2013-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT01756768

Locations: 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: PD-0332991

First Posted Date: 2012-12-27

Last Posted Date: 2015-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT01756781

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy